Edwards Lifesciences Reports Fourth Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Edwards Lifesciences (EW) PT Raised to $174 at Canaccord Genuity
February 2, 2018 7:08 AM ESTCanaccord Genuity raised its price target on Edwards Lifesciences (NYSE: EW) to $174.00 (from $140.00) while maintaining a Buy rating. An analysis suggests the stock should trade to at least $174 by year-end, based solely on the fundamentals currently evident in the business, let alone... More
Edwards Lifesciences (EW) Tops Q4 EPS by 3c; Raises Outlook
February 1, 2018 4:17 PM ESTEdwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.94, $0.03 better than the analyst estimate of $0.91. Revenue for the quarter came in at $888.5 million versus the consensus estimate of $867.09 million.
GUIDANCE:
Edwards Lifesciences sees Q1 2018 EPS of $1.04-$1.14. Edwards Lifesciences sees Q1 2018... More
